All‐cause and cardiovascular mortality risk after surgery versus radioiodine treatment for hyperthyroidism. BJS 2018; 105: 279-286.
Published: 8th November 2017
Authors: P. Giesecke, V. Frykman, G. Wallin, S. Lönn, A. Discacciati, O. Törring et al.
Little is known about the long‐term side‐effects of different treatments for hyperthyroidism. The few studies previously published on the subject either included only women or focused mainly on cancer outcomes. This register study compared the impact of surgery
Healthcare registers were used to find hyperthyroid patients over 35 years of age who were treated with radioiodine or surgery between 1976 and 2000. Comparisons between treatments were made to assess all‐cause and cause‐specific deaths to 2013. Three different statistical methods were applied: Cox regression, propensity score matching and inverse probability weighting.
Of the 10 992 patients included, 10 250 had been treated with radioiodine (mean age 65·1 years; 8668 women, 84·6 per cent) and 742 had been treated surgically (mean age 44·1 years; 633 women, 85·3 per cent). Mean duration of follow‐up varied between 16·3 and 22·3 years, depending on the statistical method used. All‐cause mortality was significantly lower among surgically treated patients, with a hazard ratio of 0·82 in the regression analysis, 0·80 in propensity score matching and 0·85 in inverse probability weighting. This was due mainly to lower cardiovascular mortality in the surgical group. Men in particular seemed to benefit from surgery compared with radioiodine treatment.
Compared with treatment with radioiodine, surgery for hyperthyroidism is associated with a lower risk of all‐cause and cardiovascular mortality in the long term. This finding was more evident among men.Read more
You may also be interested in
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra‐appendicular origin.
Authors: J.‐B. Delhorme, F. Severac, G. Averous, O. Glehen, G. Passot, N. Bakrin et al.
Notes: Survival similar
Randomized clinical trial
Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery.
Authors: J. Vidal Fortuny, S. M. Sadowski, V. Belfontali, S. Guigard, A. Poncet, F. Ris et al.
Notes: Simplifies post‐op monitoring
Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis. BJS 2018; 105: 270-278.
Authors: H. I. Kim, T. H. Kim, J.‐H. Choe, J.‐H. Kim, J. S. Kim, Y. N. Kim et al.
Notes: Volume is key
Effect of parathyroidectomy on quality of life and non‐specific symptoms in normocalcaemic primary hyperparathyroidism. BJS 2018; 105: 223-229.
Authors: S. Bannani, N. Christou, C. Guérin, A. Hamy, F. Sebag, M. Mathonnet et al.
Notes: Little improvement
Systematic review and simulation study of ignoring clustered data in surgical trials. BJS 2018; 105: 182-191.
Authors: S. Dell‐Kuster, R. A. Droeser, J. Schäfer, V. Gloy, H. Ewald, S. Schandelmaier et al.
Notes: A statistical lesson
Authors: J. Church
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Authors: D. C. Winter, M. Sund
Authors: S. A. Liu, C. C. Wang, R. S. Jiang, W. Y. Wang, J. C. Lin
Notes: Microsatellite instability predicts recurrence
Authors: A. M. Altman, J. Y. C. Hui, T. M. Tuttle
Notes: Can be significant
Authors: H. M. Rossitti, P. Söderkvist, O. Gimm
Notes: Genotype dictates type of surgery